mefenamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory, anthranilic acid derivatives 1663 61-68-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mefenamic acid
  • mefenacid
  • mephenamic acid
  • mefenamate
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
  • Molecular weight: 241.29
  • Formula: C15H15NO2
  • CLOGP: 5.14
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 2
  • TPSA: 49.33
  • ALOGS: -4.25
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 74.01 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.950 Moderate 0.71
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.389 Moderate 0.71
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 92.257 10^-6 cm/s Moderate 0.71
dh-clint Dog hepatocyte intrinsic clearance 137.721 uL/min/10^6 cells Moderate 0.71
dppb Dog plasma protein binding (% unbound) 0.400 % Moderate 0.71
fcs-ppb Fetal calf serum protein binding (% unbound) 0.610 % Moderate 0.71
herg hERG pIC50 4.308 pIC50 Moderate 0.71
hh-clint Human hepatocyte intrinsic clearance 116.145 uL/min/10^6 cells Moderate 0.71
hlm-clint Human liver microsomal intrinsic clearance 29.580 uL/min/mg protein Moderate 0.71
hppb Human plasma protein binding (% unbound) 0.290 % Moderate 0.71
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 60
kinase-selectivity-class ACVR2A,ACVR2B,AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,JAK1,MAP2K6,MAPK7,MTOR,PDK4,SIK2,SIK3,STK33,TEK,TTK 21
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.065 Moderate 0.71
mh-clint Mouse hepatocyte intrinsic clearance 118.850 Moderate 0.71
mppb Mouse plasma protein binding (% unbound) 1.030 Moderate 0.71
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.897 Moderate 0.71
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 0.980 % Moderate 0.71
rh-clint Rat hepatocyte intrinsic clearance 201.837 uL/min/10^6 cells Moderate 0.71
rh-fuinc Rat hepatocyte fraction unbound in incubation 50.630 % Moderate 0.71
rppb Rat plasma protein binding (% unbound) 0.270 % Moderate 0.71
solubility-dd Solubility at pH 7.4 in DMSO 763.836 uM Moderate 0.71

Approvals:

DateAgencyCompanyOrphan
March 28, 1967 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion site coldness 119.88 14.20 21 9885 214 90618327
Vascular malformation 112.35 14.20 24 9882 728 90617813
Gamma-glutamyltransferase decreased 110.88 14.20 21 9885 340 90618201
Paranasal cyst 110.58 14.20 24 9882 786 90617755
Mastoiditis 93.30 14.20 24 9882 1646 90616895
Spinal pain 84.45 14.20 39 9867 15728 90602813
Infusion site induration 80.29 14.20 21 9885 1538 90617003
Stress 79.37 14.20 68 9838 81327 90537214
Mean cell haemoglobin decreased 71.69 14.20 26 9880 5669 90612872
Post-traumatic neck syndrome 70.36 14.20 21 9885 2493 90616048
Vasodilatation 67.52 14.20 21 9885 2863 90615678
Otitis media 63.59 14.20 24 9882 5846 90612695
Feeling cold 58.99 14.20 37 9869 27428 90591113
Infusion site haemorrhage 54.58 14.20 21 9885 5390 90613151
Vein disorder 54.11 14.20 21 9885 5515 90613026
Inflammatory marker increased 49.99 14.20 23 9883 9191 90609350
Retinal detachment 49.86 14.20 21 9885 6801 90611740
Peripheral coldness 46.58 14.20 25 9881 13867 90604674
Incontinence 44.55 14.20 24 9882 13411 90605130
Urinoma 43.53 14.20 7 9899 40 90618501
Blood creatinine decreased 37.66 14.20 17 9889 6498 90612043
Oropharyngeal pain 35.85 14.20 53 9853 115134 90503407
Gastroenteritis radiation 35.71 14.20 9 9897 568 90617973
Bladder prolapse 35.41 14.20 12 9894 2143 90616398
Tendon disorder 34.09 14.20 16 9890 6684 90611857
Injection site bruising 32.38 14.20 34 9872 52273 90566268
Dactylitis 31.95 14.20 13 9893 3860 90614681
Chills 31.78 14.20 54 9852 131927 90486614
Musculoskeletal disorder 31.58 14.20 23 9883 21746 90596795
Neutrophil count decreased 31.54 14.20 39 9867 71493 90547048
Oral lichenoid reaction 31.40 14.20 6 9900 102 90618439
Angioedema 31.26 14.20 37 9869 64839 90553702
Toothache 31.15 14.20 23 9883 22207 90596334
Rectal prolapse 30.98 14.20 11 9895 2256 90616285
Skin sensitisation 30.68 14.20 9 9897 1006 90617535
Urine osmolarity increased 30.52 14.20 6 9900 119 90618422
Disturbance in attention 29.83 14.20 31 9875 47078 90571463
Body temperature decreased 29.74 14.20 23 9883 23793 90594748
Pain in jaw 29.36 14.20 31 9875 47954 90570587
Poor venous access 29.17 14.20 21 9885 19506 90599035
Headache 28.47 14.20 176 9730 862570 89755971
Blood potassium increased 28.02 14.20 21 9885 20728 90597813
Enthesopathy 26.25 14.20 15 9891 9389 90609152
Dizziness 25.22 14.20 129 9777 589155 90029386
Metastases to bone 24.21 14.20 21 9885 25484 90593057
Arteriospasm coronary 22.47 14.20 11 9895 5039 90613502
Nephrogenic diabetes insipidus 22.44 14.20 7 9899 963 90617578
Systemic lupus erythematosus 22.30 14.20 6 9900 361890 90256651
Thermal burn 22.19 14.20 12 9894 6750 90611791
Gastritis 22.10 14.20 25 9881 41728 90576813
Therapeutic response decreased 21.97 14.20 37 9869 89692 90528849
Photosensitivity reaction 21.80 14.20 17 9889 17790 90600751
Eosinophil count increased 21.70 14.20 15 9891 13066 90605475
Hepatic function abnormal 21.64 14.20 26 9880 46262 90572279
Haemangioma 21.02 14.20 9 9897 3033 90615508
Pemphigus 20.94 14.20 5 9901 326859 90291682
Renal ischaemia 20.55 14.20 6 9900 660 90617881
Injection site inflammation 20.53 14.20 10 9896 4531 90614010
Renal papillary necrosis 20.44 14.20 5 9901 279 90618262
Drug reaction with eosinophilia and systemic symptoms 19.96 14.20 24 9882 42734 90575807
Cerebellar haemangioma 19.74 14.20 4 9902 93 90618448
Flushing 19.72 14.20 35 9871 88456 90530085
White blood cell count decreased 19.69 14.20 51 9855 167058 90451483
Rabbit syndrome 19.55 14.20 5 9901 335 90618206
Gastrointestinal inflammation 19.55 14.20 11 9895 6685 90611856
Death 19.49 14.20 13 9893 456538 90162003
Impaired driving ability 19.30 14.20 10 9896 5163 90613378
Post herpetic neuralgia 18.74 14.20 8 9898 2676 90615865
Wound 18.70 14.20 5 9901 302975 90315566
Mononeuropathy multiplex 18.69 14.20 5 9901 399 90618142
Glossodynia 18.60 14.20 6 9900 321773 90296768
Injection site mass 18.60 14.20 17 9889 22073 90596468
Tremor 18.30 14.20 47 9859 153126 90465415
Vitamin D decreased 18.16 14.20 13 9893 11966 90606575
Hand deformity 18.09 14.20 5 9901 296357 90322184
Throat tightness 17.95 14.20 19 9887 29465 90589076
Anxiety 17.80 14.20 74 9832 309698 90308843
Menopausal symptoms 17.69 14.20 8 9898 3070 90615471
Arthritis 17.63 14.20 49 9857 167266 90451275
Platelet count decreased 17.38 14.20 43 9863 136926 90481615
Crystal nephropathy 17.32 14.20 6 9900 1145 90617396
Abdominal pain upper 17.22 14.20 77 9829 332597 90285944
Blood pressure decreased 17.17 14.20 30 9876 74865 90543676
Injection site erythema 17.06 14.20 35 9871 98467 90520074
Arthropod bite 16.81 14.20 11 9895 8756 90609785
Injection site haemorrhage 16.80 14.20 18 9888 28300 90590241
Tubulointerstitial nephritis 16.62 14.20 17 9889 25326 90593215
Immunodeficiency 16.58 14.20 22 9884 43212 90575329
Vitamin B12 decreased 16.26 14.20 9 9897 5301 90613240
Citric acid urine increased 16.05 14.20 3 9903 45 90618496
Familial haemophagocytic lymphohistiocytosis 15.99 14.20 3 9903 46 90618495
Bone pain 15.76 14.20 26 9880 61957 90556584
Heavy menstrual bleeding 15.75 14.20 15 9891 20515 90598026
Hypogeusia 15.58 14.20 6 9900 1543 90616998
Tongue discomfort 15.30 14.20 7 9899 2758 90615783
Alopecia 15.29 14.20 19 9887 495052 90123489
Granulocyte percentage 15.29 14.20 3 9903 59 90618482
Feeling hot 15.05 14.20 29 9877 77979 90540562
Urine output increased 14.83 14.20 6 9900 1756 90616785
Lipaemic index score 14.45 14.20 3 9903 79 90618462
Influenza like illness 14.38 14.20 29 9877 80582 90537959
Pain in extremity 14.21 14.20 91 9815 450438 90168103

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Heat stroke 65.34 22.96 14 1861 1094 42618366
Ankylosing spondylitis 59.58 22.96 19 1856 7037 42612423
Brain stem syndrome 36.79 22.96 8 1867 669 42618791
Mydriasis 36.72 22.96 14 1861 8756 42610704
Exposure to communicable disease 33.05 22.96 6 1869 198 42619262
Anhidrosis 32.52 22.96 6 1869 217 42619243
Lid sulcus deepened 29.76 22.96 5 1870 104 42619356
Vanishing bile duct syndrome 28.71 22.96 8 1867 1863 42617597
Alopecia 25.66 22.96 16 1859 29260 42590200

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vascular malformation 118.98 14.90 25 10731 789 110577754
Infusion site coldness 118.73 14.90 21 10735 258 110578285
Paranasal cyst 116.37 14.90 25 10731 879 110577664
Gamma-glutamyltransferase decreased 111.12 14.90 21 10735 380 110578163
Mastoiditis 90.02 14.90 25 10731 2586 110575957
Infusion site induration 85.32 14.90 21 10735 1355 110577188
Post-traumatic neck syndrome 72.12 14.90 21 10735 2574 110575969
Mean cell haemoglobin decreased 68.80 14.90 26 10730 7148 110571395
Spinal pain 67.75 14.90 34 10722 18481 110560062
Vasodilatation 64.53 14.90 21 10735 3723 110574820
Otitis media 64.19 14.90 25 10731 7451 110571092
Infusion site haemorrhage 60.30 14.90 21 10735 4577 110573966
Stress 59.99 14.90 62 10694 105286 110473257
Feeling cold 58.16 14.90 38 10718 33949 110544594
Vein disorder 53.95 14.90 21 10735 6249 110572294
Heat stroke 46.53 14.90 14 10742 1921 110576622
Peripheral coldness 42.56 14.90 25 10731 18515 110560028
Retinal detachment 42.43 14.90 21 10735 11079 110567464
Incontinence 42.37 14.90 24 10732 16611 110561932
Bladder prolapse 41.54 14.90 12 10744 1430 110577113
Angioedema 39.00 14.90 48 10708 98452 110480091
Oropharyngeal pain 36.91 14.90 55 10701 135221 110443322
Headache 36.61 14.90 176 10580 882201 109696342
Injection site bruising 36.30 14.90 34 10722 51229 110527314
Death 35.31 14.90 12 10744 698857 109879686
Toothache 34.67 14.90 24 10732 23551 110554992
Blood creatinine decreased 34.07 14.90 17 10739 9120 110569423
Gastroenteritis radiation 33.75 14.90 9 10747 799 110577744
Urinoma 32.26 14.90 7 10749 258 110578285
Rectal prolapse 30.91 14.90 11 10745 2552 110575991
Disturbance in attention 30.88 14.90 34 10722 61961 110516582
Skin sensitisation 30.85 14.90 9 10747 1110 110577433
Bone pain 29.50 14.90 34 10722 65099 110513444
Oral lichenoid reaction 28.72 14.90 6 10750 184 110578359
Body temperature decreased 27.12 14.90 25 10731 36910 110541633
Poor venous access 27.08 14.90 21 10735 24501 110554042
Inflammatory marker increased 26.78 14.90 17 10739 14452 110564091
Chills 26.77 14.90 58 10698 190522 110388021
Musculoskeletal disorder 26.33 14.90 20 10736 22644 110555899
Urine osmolarity increased 25.99 14.90 6 10750 294 110578249
Injection site haemorrhage 25.51 14.90 23 10733 33005 110545538
Pain in jaw 25.37 14.90 28 10728 51149 110527394
Anhidrosis 24.12 14.90 6 10750 404 110578139
Tendon disorder 23.89 14.90 13 10743 8324 110570219
Blood potassium increased 23.43 14.90 22 10734 33227 110545316
Therapeutic response decreased 23.18 14.90 37 10719 96462 110482081
Haemangioma 22.71 14.90 9 10747 2807 110575736
Metastases to bone 22.58 14.90 21 10735 31351 110547192
Lid sulcus deepened 22.48 14.90 5 10751 207 110578336
Injection site erythema 22.47 14.90 36 10720 94140 110484403
Neutrophil count decreased 22.00 14.90 41 10715 120900 110457643
Vanishing bile duct syndrome 21.68 14.90 9 10747 3159 110575384
Thermal burn 21.63 14.90 12 10744 7976 110570567
Influenza like illness 21.37 14.90 34 10722 88378 110490165
Post herpetic neuralgia 21.33 14.90 9 10747 3292 110575251
Arthritis 21.28 14.90 49 10707 167537 110411006
Injection site inflammation 21.17 14.90 10 10746 4761 110573782
Gastritis 20.98 14.90 26 10730 53673 110524870
Abdominal pain upper 20.92 14.90 78 10678 349033 110229510
Immunodeficiency 20.56 14.90 22 10734 38816 110539727
Cerebellar haemangioma 20.21 14.90 4 10752 93 110578450
Menopausal symptoms 20.19 14.90 8 10748 2493 110576050
Pain in extremity 20.00 14.90 97 10659 487021 110091522
Dizziness 19.95 14.90 126 10630 698067 109880476
Rabbit syndrome 19.46 14.90 5 10751 384 110578159
Vitamin D decreased 19.30 14.90 13 10743 12202 110566341
Crystal nephropathy 18.79 14.90 7 10749 1849 110576694
Renal papillary necrosis 18.75 14.90 5 10751 444 110578099
Injection site mass 18.73 14.90 17 10739 24596 110553947
Impaired driving ability 18.44 14.90 10 10746 6360 110572183
Mydriasis 18.24 14.90 16 10740 22141 110556402
Heavy menstrual bleeding 18.04 14.90 14 10742 16351 110562192
Vitamin B12 decreased 17.33 14.90 9 10747 5248 110573295
Urticaria 17.26 14.90 69 10687 318788 110259755
Nephrogenic diabetes insipidus 16.92 14.90 7 10749 2438 110576105
Enthesopathy 16.72 14.90 12 10744 12466 110566077
Ankylosing spondylitis 16.44 14.90 13 10743 15599 110562944
Citric acid urine increased 16.05 14.90 3 10753 51 110578492
Throat tightness 16.04 14.90 18 10738 33471 110545072
Flushing 16 14.90 33 10723 104703 110473840
Stem cell transplant 15.81 14.90 8 10748 4419 110574124
Tongue discomfort 15.79 14.90 7 10749 2881 110575662
Familial haemophagocytic lymphohistiocytosis 15.68 14.90 3 10753 58 110578485
Feeling hot 15.47 14.90 30 10726 91076 110487467
Injection site swelling 15.26 14.90 24 10732 61766 110516777
Infusion site pain 15.19 14.90 13 10743 17406 110561137
Granulocyte percentage 15.03 14.90 3 10753 73 110578470
Eosinophil count increased 14.97 14.90 14 10742 21044 110557499

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AG01 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Fenamates
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35493 antipyretic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:78298 environmental contaminant
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug

Related Drugs by ATC class:

M01AG Fenamates 3 drugs
flufenamic acidmeclofenamic acidtolfenamic acid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Dysmenorrhea indication 266599000
Vascular headache off-label use 128187005
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Blood coagulation disorder contraindication 64779008 DOID:1247
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.43 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.83 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 4.78 WOMBAT-PK CHEMBL
Calcium-activated potassium channel subunit alpha-1 Ion channel ACTIVATOR EC50 4 IUPHAR
Dihydrofolate reductase Enzyme Ki 4.14 CHEMBL
Cytochrome P450 2C9 Enzyme EC50 5.30 WOMBAT-PK
Aldose reductase Enzyme IC50 4.11 CHEMBL
Aldo-keto reductase family 1 member C1 Enzyme Ki 6.09 CHEMBL
Aldo-keto reductase family 1 member C2 Enzyme Ki 6.66 CHEMBL
Aldo-keto reductase family 1 member C3 Enzyme Ki 6.52 CHEMBL
Myeloperoxidase Enzyme IC50 6.01 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 4.80 CHEMBL
Aldo-keto reductase family 1 member B10 Enzyme IC50 5.80 CHEMBL
Nicotinate phosphoribosyltransferase Enzyme Ki 10.30 CHEMBL
Acetylcholinesterase Enzyme IC50 5.21 CHEMBL
NACHT, LRR and PYD domains-containing protein 3 Cytosolic other IC50 4.60 CHEMBL

External reference:

IDSource
4019082 VUID
N0000147343 NUI
D00151 KEGG_DRUG
4019082 VANDF
C0025152 UMLSCUI
CHEBI:6717 CHEBI
ID8 PDB_CHEM_ID
CHEMBL686 ChEMBL_ID
DB00784 DRUGBANK_ID
D008528 MESH_DESCRIPTOR_UI
4044 PUBCHEM_CID
2593 IUPHAR_LIGAND_ID
1494 INN_ID
367589PJ2C UNII
257844 RXNORM
5034 MMSL
91405 MMSL
d00285 MMSL
001578 NDDF
116727007 SNOMEDCT_US
34364009 SNOMEDCT_US
387185008 SNOMEDCT_US
367589PJ2C INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mefenamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 0276-0509 CAPSULE 250 mg ORAL ANDA 26 sections
Mefenamic acid HUMAN PRESCRIPTION DRUG LABEL 1 42571-258 CAPSULE 250 mg ORAL ANDA 27 sections
Mefenamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 68180-185 CAPSULE 250 mg ORAL ANDA 25 sections
Mefenamic acid HUMAN PRESCRIPTION DRUG LABEL 1 72162-2382 CAPSULE 250 mg ORAL ANDA 27 sections
Mefenamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 80425-0306 CAPSULE 250 mg ORAL ANDA 12 sections
Mefenamic Acid HUMAN PRESCRIPTION DRUG LABEL 1 80425-0423 CAPSULE 250 mg ORAL ANDA 23 sections